Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

被引：0
|
作者：
Moura, Filipe A.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John
Gause-nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13182
引用
收藏
页数：3
相关论文
共 50 条
  • [41] SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL
    Haller, Paul
    Wiviott, Stephen
    Jarolim, Petr
    Goodrich, Erica L.
    Bhatt, Deepak L.
    Gause-Nilsson, Ingrid
    Leiter, Lawrence A.
    McGuire, Darren K.
    Raz, Itamar
    Wilding, John
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 378 - 378
  • [42] A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
    Berg, David
    Wiviott, Stephen D.
    Raz, Itamar
    Kamanu, Frederick
    Im, KyungAh
    Cahn, Avivit
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Jarolim, Petr
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Huo, Yong
    Lopez-Sendon, Jose L.
    Ardissino, Diego
    Gause-Nilsson, Ingrid A.
    Sabatine, Marc S.
    Morrow, David A.
    CIRCULATION, 2020, 142
  • [43] Galectin-3 and Progression of Kidney Disease in Patients With Type 2 Diabetes Mellitus: Analyses From the DECLARE-TIMI 58 Trial
    Haller, Paul
    Wiviott, Stephen
    Berg, David
    Jarolim, Petr
    Goodrich, Erica
    Bhatt, Deepak
    Cahn, Avivit
    Gause-Nilsson, Ingrid
    Leiter, Lawrence
    McGuire, Darren
    Raz, Itamar
    Wilding, John
    Sabatine, Marc
    Morrow, David
    CIRCULATION, 2024, 150
  • [44] Series: Cardiovascular outcome trials for diabetes drugs Canagliflozin and the CANVAS Program, dapagliflozin and DECLARE-TIMI 58, ertugliflozin and VERTIS CV
    Fisher, Miles
    BRITISH JOURNAL OF DIABETES, 2021, 21 (02): : 241 - 246
  • [45] Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58
    Kang, Yu Mi
    Melloni, Giorgio E. M.
    Cahn, Avivit
    Raz, Itamar
    Moura, Filipe
    Bhatt, Deepak L.
    Inzucchi, Silvio E.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Oscarsson, Jan
    Marston, Nicholas
    Ruff, Christian T.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES, 2024, 73
  • [46] Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study
    Cahn, A.
    Raz, I.
    Leiter, L. A.
    Mosenzon, O.
    Murphy, S. A.
    Bhatt, D. L.
    McGuire, D. K.
    Wilding, J. P. H.
    Gause-Nilsson, I. A. M.
    Langkilde, A.
    Sabatine, M.
    Wiviott, S. D.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S269 - S269
  • [47] Effects of dapagliflozin on weight loss and metabolic changes in type 2 diabetes patients fasting in the month of Ramadan
    Seman, W. Wan
    Rajoo, S.
    Noor, N. Mohd
    Kori, N.
    Sukor, N.
    Wahab, N. A.
    Mustufa, N.
    Kamaruddin, N.
    DIABETOLOGIA, 2016, 59 : S346 - S346
  • [48] SGLT2-independent metabolic Effects of Dapagliflozin in Patients with Type 2 Diabetes
    Kahl, S.
    DIABETOLOGE, 2016, 12 (07): : 498 - 499
  • [49] Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
    Kishimoto, Shinji
    Higashi, Yukihito
    Imai, Takumi
    Eguchi, Kazuo
    Fukumoto, Kazuo
    Tomiyama, Hirofumi
    Maemura, Koji
    Tanaka, Atsushi
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [50] Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
    Shinji Kishimoto
    Yukihito Higashi
    Takumi Imai
    Kazuo Eguchi
    Kazuo Fukumoto
    Hirofumi Tomiyama
    Koji Maemura
    Atsushi Tanaka
    Koichi Node
    Cardiovascular Diabetology, 22
12345